Dr. Hugh Levaux, Former CEO of Ninaza, Joins Medidata Solutions as Vice President of Product Strategy

Medidata Solutions, a global provider of electronic clinical data
capture, management and reporting solutions, today announced the
addition of Dr. Hugh Levaux as vice president of product strategy. In
this role, Levaux will draw on more than 15 years of experience in
pharmaceutical outsourcing, strategic consulting and health outcomes
research, as well as expertise in early phase clinical development,
late phase registries and safety surveillance programs. Levaux will be
responsible for the overall definition and management of Medidata's
product offerings, working to bring together Medidata Rave
implementation, hosting and support services to address new and
existing market segments and customer requirements.

Levaux joins Medidata from Ninaza, a recent provider of web-based
electronic data capture (EDC) solutions. As CEO of Ninaza, he set
strategic direction for the company and oversaw daily operations with
a specific focus on product development, commercial operations and
professional services. Prior to joining Ninaza, Levaux held positions
as vice president and general manager of the
pharmaceutical/biotechnology practice at CareScience, a supplier of
web-based patient database and analysis software. He also previously
served as senior vice president at Quintiles Transnational, directing
international late phase sales and clinical operations.

"I am very excited to apply my experience in EDC technology,
professional services and product development to my new role at
Medidata, a company that has been consistently driving the evolution
of the e-clinical process," Levaux said. "Medidata's innovation and
advancements - from both a technology and services perspective -
continue to make a significant impact on the way sponsors conduct
clinical trials. I look forward to collaborating with a talented team
that is committed to customer success to create new market
opportunities for Rave."

Prior to Quintiles, Levaux worked as an analyst for RAND
Corporation, where he performed risk assessment on emerging markets
and evaluated the adoption of commercial processes and technologies
with government and private sector clients. Levaux holds a Ph.D. in
policy analysis from the RAND Graduate School and has also received
master's degrees in international economics and international
relations from SAIS at Johns Hopkins University and international
politics from Universite Libre de Bruxelles in Belgium. Additionally,
Levaux's work has been published in leading academic and clinical
journals.

"With our launch of Medidata Rave 5.6 earlier this year, Hugh's
ability to implement strategic product initiatives will be invaluable
as we continue to meet increasing market demand for Rave and for our
expertise in clinical software integration," said Glen de Vries, chief
technology officer of Medidata Solutions. "Hugh's experience will help
us shape how we develop new features in Rave and add critical services
that will allow us to approach new customers and enter new markets. We
are excited for Hugh to join Medidata, and see his addition to the
team as a reflection of the high quality products and services we
provide as well as the appeal of our skilled leadership team."

About Medidata Solutions Worldwide

Medidata Solutions helps the world's leading pharmaceutical,
biotechnology, medical device and research organizations maximize the
value of their clinical research investments. Innovative process
design, technology and services streamline clinical trials by
providing early visibility to reliable clinical data - the lifeblood
of every research organization. Working with companies and
institutions both large and small, Medidata Solutions helps clinical
researchers safely accelerate the process of bringing life-enhancing
treatments to market - on six continents and in more than 80
countries. Medidata Solutions brings significant value to its broad
client base with deep clinical experience and expertise in more than
20 therapeutic areas, projects in Phase I, II, III, IV, registries and
surveillance, and studies with thousands of investigators and
tens-of-thousands of subjects. For more information, please visit
www.mdsol.com.